Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
3.38% $4.59
America/New_York / 25 apr 2024 @ 12:26
FUNDAMENTALS | |
---|---|
MarketCap: | 24.40 mill |
EPS: | -3.14 |
P/E: | -1.460 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 5.32 mill |
Avg Daily Volume: | 0.0645 mill |
RATING 2024-04-25 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | ||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.460 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.25x |
Company: PE -1.460 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.898 (-80.45%) $-3.69 |
Date: 2024-04-25 |
Expected Trading Range (DAY) |
---|
$ 4.21 - 4.97 ( +/- 8.32%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Patel Mahesh V. | Buy | 4 893 | Common Stock |
2024-03-08 | Fogarty Krista | Buy | 991 | Common Stock |
2023-05-25 | Patel Mahesh V. | Buy | 8 706 | Common Stock |
2023-05-10 | Papapetropoulos Spyros | Buy | 30 000 | Stock Option (Right to Buy) |
2023-05-10 | Higuchi John W. | Buy | 30 000 | Common Stock (Right to Buy) |
INSIDER POWER |
---|
93.73 |
Last 96 transactions |
Buy: 4 769 643 | Sell: 1 163 369 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.59 (3.38% ) |
Volume | 0.0053 mill |
Avg. Vol. | 0.0645 mill |
% of Avg. Vol | 8.28 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.